SavedAdd your journal

Journals / Kafkas Üniversitesi Veteriner Fakültesi Dergisi / 2015 / Cilt: 21 - Sayı: 6

SIRT2 - JAK1 Etkileşimi Kanser Hücrelerindeki IL-6'in Neden Olduğu İnflamatuar Tepkiyi Azaltır.

SIRT2 - JAK1 Interaction Decreases IL-6 Induced Inflammatory Response in Cancer Cells

ÖZKAN ÖZDEN
Pages
813–817
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These results suggest that SIRT2 has a protective role against chronic inflammatory diseases including inflammationassociated cancer

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Interleukin-6 (IL-6) is a pro-inflammatory cytokine critical in immunoregulation.
📊
Key Findings & Data:Aberrant IL-6 signaling has been implicated in various diseases including inflammation-associated cancer.
💡
Conclusion & Impact:These results suggest that SIRT2 has a protective role against chronic inflammatory diseases including inflammationassociated cancer
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Interleukin-6 (IL-6) is a pro-inflammatory cytokine critical in immunoregulation. Aberrant IL-6 signaling has been implicated in various diseases including inflammation-associated cancer. Sirtuin-2 (SIRT2) is a cytoplasmic deacetylase and is generally considered a tumor suppressor. SIRT2 gene removed mouse develops tumors in many organs, primarily in the liver and breast tissues as the mouse ages. The purpose of the study was to investigate the roles of SIRT2 on IL-6 induced inflammatory response in mouse embryonic fibroblasts (MEFs) with SIRT2 gene removed and HeLa cervical cancer cell lines that overexpress SIRT2 gene. Immunoprecipitation and immunoblotting techniques were utilized in the study. SIRT2 interacts with JAK1, which is one of the downstream proteins of IL-6. We also found that overexpression of SIRT2 in HeLa cervical cancer cells decreases IL-6 induced inflammatory response by decreasing the activity of JAK1. These results suggest that SIRT2 has a protective role against chronic inflammatory diseases including inflammationassociated cancer

Özet

İnterlökin-6 (IL-6), bağışıklık sisteminin düzenlenmesinde kritik bir pro-inflamatuar sitokindir. Anormal IL-6 sinyalinin, inflamatuara bağlı kanser de dahil olmak üzere çeşitli hastalıklarda rol oynadığı gösterilmiştir. Sirtuin-2 (SIRT2), sitoplazmik bir diasetilaz olup, genellikle tümör baskılayıcı olarak kabul edilir. SIRT2 geni çıkarılmış fare yaşlandıkça, başlica karaciğer ve meme dokusunda, ve pek çok organında tümörler gelişir. Bu çalışmanın amacı, SIRT2 geni çıkarılmış embriyonik fare fibroblastlarda (MEF'ler) ve SIRT2 genini aşırı eksprese eden HeLa servikal kanser hücrelerinde SIRT2'nin, IL-6 tarafından tetiklenen inflamatuar yanıtı üzerindeki rollerini araştırmaktı. Bu çalışmada immunolojik çökeltme ve immüno-inkube teknikleri kullanılmıştır. SIRT2, IL-6'nın aşağı tarafındaki takım proteinlerinden biri olan JAK1 ile etkileşime girer. HeLa servikal kanser hücrelerinde, SIRT2'nin aşırı ekspresyonu, JAK1'in aktivitesini azaltarak, IL-6'in neden olduğu inflamatuar yanıtı azalır. Bu sonuçlar, SIRT2 proteinin, kronik inflamatuar hastalıklara ve inflamatuara-bağlı kansere karşı koruyucu bir rol oynadığını önermektedir

🔖

Cite This Article

ÖZDEN, Ö. (2015). SIRT2 - JAK1 Etkileşimi Kanser Hücrelerindeki IL-6'in Neden Olduğu İnflamatuar Tepkiyi Azaltır.. Kafkas Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 21 - Sayı: 6, 813–817. https://ajindex.com/articles/272543

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G: Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature, 368, 339-, 1994. DOI: 10.1038/368339a0 Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M, Kishimoto T: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell, 77, 63-71, 1994. DOI: 1016/0092-8674(94)90235-6
  2. Rath T, Billmeier U, Waldner MJ, Atreya R, Neurath MF: From physiology to disease and targeted therapy: Interleukin-6 in inflammation and inflammation-associated carcinogenesis. Arch Toxicol, 89, 541-554, DOI: 10.1007/s00204-015-1461-5
  3. Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J Clin Endocrinol Metab, 85, 3338-3342, 2000.
  4. Balkwill F, Mantovani A: Inflammation and cancer: Back to Virchow? Lancet, 357, 539-545, 2001. DOI: 10.1016/S0140-6736(00)04046-0
  5. Mauer J, Denson JL, Bruning JC: Versatile functions for IL-6 in metabolism and cancer. Trends Immunol, 36, 92-101, 2015. DOI: 10.1016/j. it.2014.12.008 Nakashima J, Tachibana M, Horiguchi Y, Oya M, Ohigashi T, Asakura H, Murai M: Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res, 6, 2702-2706, 2000.
  6. Neurath MF, Finotto S: IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer. Cytokine Growth Factor Rev, 22, 83-89, 2011. DOI: 10.1016/j.cytogfr.2011.02.003 Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, Li C, Veenstra TD, Li B, Yu H, Ji J, Wang XW, Park SH, Cha YI, Gius D, Deng CX: SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell, 20, 487-499, 2011. DOI: 1016/j.ccr.2011.09.004 Park SH, Zhu Y, Ozden O, Kim HS, Jiang H, Deng CX, Gius D, Vassilopoulos A: SIRT2 is a tumor suppressor that connects aging, acetylome, cell cycle signaling, and carcinogenesis. Transl Cancer Res, 1, 21, 2012.
  7. Kim MJ, Kim DW, Park JH, Kim SJ, Lee CH, Yong JI, Ryu EJ, Cho SB, Yeo HJ, Hyeon J, Cho SW, Kim DS, Son O, Park J, Han KH, Cho YS, Eum WS, Choi SY: PEP-1-SIRT2 inhibits inflammatory response and oxidative stress-induced cell death via expression of antioxidant enzymes in murine macrophages. Free Radic Biol Med, 6